Oryzon Genomics
ORY.MCOryzon Genomics leverages its proprietary epigenetic platform to discover and develop personalized therapeutics for oncology and CNS diseases. As a publicly traded company, it has advanced its lead LSD1 inhibitor, iadademstat, into multiple Phase II trials, including for acute myeloid leukemia (AML) and essential thrombocythemia, while also expanding its patent portfolio globally. The company's strategy focuses on biomarker-driven development and combination therapies, particularly with immuno-oncology agents, to address significant unmet medical needs.
ORY.MC · Stock Price
Historical price data
AI Company Overview
Oryzon Genomics leverages its proprietary epigenetic platform to discover and develop personalized therapeutics for oncology and CNS diseases. As a publicly traded company, it has advanced its lead LSD1 inhibitor, iadademstat, into multiple Phase II trials, including for acute myeloid leukemia (AML) and essential thrombocythemia, while also expanding its patent portfolio globally. The company's strategy focuses on biomarker-driven development and combination therapies, particularly with immuno-oncology agents, to address significant unmet medical needs.
Technology Platform
Proprietary epigenetic platform focusing on histone modifiers, DNA methyltransferases, and chromatin remodelers to identify novel drug targets and biomarkers for personalized cancer and CNS therapies.
Pipeline
6| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Iadademstat + Paclitaxel | Small-cell Lung Cancer | Phase 2 | |
| vafidemstat + Placebo | Borderline Personality Disorder | Phase 2 | |
| ORY-2001 Low dose + ORY-2001 High dose + Placebo | Mild to Moderate Alzheimer's Disease | Phase 2 | |
| Iadademstat + Atezolizumab | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | Phase 1 | |
| Azacitidine + Iadademstat + Venetoclax | Acute Myeloid Leukemia | Phase 1 |
Funding History
2Opportunities
Risk Factors
Competitive Landscape
Oryzon faces competition from both large pharma (GSK, Bristol Myers Squibb) and biotech peers (Imago BioSciences, Salarius) in the LSD1 inhibitor space. Differentiation is sought through biomarker-driven personalized medicine, combination therapy strategies with immuno-oncology, and pursuing both oncology and CNS indications to diversify the portfolio.